J.P. Morgan Healthcare Conference Highlights: B莲Sheng Secures $745M IPO Following $500M Strategic Investment

On January 8, 2018 (U.S. time), the annual J.P. Morgan Healthcare Conference was held as scheduled in San Francisco, attracting more than 450 listed healthcare companies and innovative enterprises, as well as over 9,000 healthcare entrepreneurs and investors.

At the conference, Bill Gates provided a detailed explanation of the investment logic behind his medical foundation. Meanwhile, CEOs from leading healthcare companies—including Johnson & Johnson, Medtronic, Abbott, Eli Lilly, Pfizer, Amgen, Merck & Co., and Illumina—shared their development strategies and the objectives they aimed to achieve in 2018.

Perspective:

1Johnson & Johnson: Creating a Crisis Could Be Good for Investors

Johnson & Johnson CEO Alex Gorsky stated that the company should manufacture a crisis, such as concerns that Amazon could disrupt its business in the future. This approach might help the company outperform the broader market.

Gorsky’s remarks on manufacturing crises are primarily aimed at the issues in the development of the healthcare sector in recent years. He believes this is “a very worthwhile time for you to think about science and technology.”

2. Medtronic: Emphasizing Value-Based Healthcare and Responding to Questions About Its M&A Strategy

Ishrak hinted that Tyrx's success was primarily linked to the fundamental drivers of healthcare:Payment for Expected Clinical Outcomes. He said, “Uncertainty in the market is inevitable sooner or later; this is a fundamental fact. In my view, paying for clinical outcomes and creating added value must be the right approach.”

Ishrak stated that since the acquisition of Covidien, Medtronic has spent $3.7 billion on acquisitions, nearly all of which were technology-driven companies. Therefore, for Medtronic, the key consideration is how to develop a promising technology and commercialize it.

3. Abbott: Completed Two Major Acquisitions in 2017, and Will Reach Two Major Milestones in 2018

In January 2017, Abbott acquired St. Jude Medical, and in the fall, it acquired Alere. The addition of St. Jude Medical and Alere has strengthened Abbott’s leadership and influence in key areas of healthcare.Alere’s rapid diagnostic technologies have been integrated into Abbott’s existing POCT business, propelling Abbott to the top position globally in the POCT market.

The combination of St. Jude Medical’s vascular business with Abbott has positioned Abbott as a leader in the cardiovascular device market, while also entering a new market: neuromodulation for the treatment of chronic pain and movement disorders.Brian Yoor stated that Abbott will increase its R&D investment and allocate additional funds to consolidate the company’s position in the global market.

Report:

Key Takeaways from Johnson & Johnson, Medtronic, Abbott, Eli Lilly, Pfizer, and Illumina at the 2018 J.P. Morgan Healthcare Conference

For more content, please visit the VCBeat Knowledge Base!